| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Dannex Ayrton Starwin Plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | GH₵0.38 |
| 52 Week High | GH₵0 |
| 52 Week Low | GH₵0 |
| Beta | 0 |
| 11 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | -5.00% |
| 33 Year Change | -5.00% |
| 5 Year Change | n/a |
| Change since IPO | -5.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| DASPHARMA | GH Pharmaceuticals | GH Market | |
|---|---|---|---|
| 7D | 0% | -2.9% | 1.1% |
| 1Y | -5.0% | 3.9% | 47.5% |
Return vs Industry: DASPHARMA underperformed the GH Pharmaceuticals industry which returned 6.5% over the past year.
Return vs Market: DASPHARMA underperformed the GH Market which returned 47.6% over the past year.
Price Volatility
| DASPHARMA volatility | |
|---|---|
| DASPHARMA Average Weekly Movement | 0% |
| Pharmaceuticals Industry Average Movement | 6.4% |
| Market Average Movement | 2.5% |
| 10% most volatile stocks in GH Market | 5.6% |
| 10% least volatile stocks in GH Market | 1.0% |
Stable Share Price: Data is not available.
Volatility Over Time: Insufficient data to determine DASPHARMA's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1964 | n/a | Daniel Kwabena Kissi | dasplcgh.com |
Dannex Ayrton Starwin Plc manufactures and sells pharmaceutical products in Ghana. It offers a range of products in various categories, such as analgesics and antipyretics, hematinics, anti-tussives, anti-convulsing and anti-asthmatics, cough preparations, dermatological products, food supplements, vitamins, and minerals. The company manufactures its products in form of syrups, tablets, creams, suspensions, disinfectants, lozenges, powders, capsules, and emulsions.
Dannex Ayrton Starwin Plc Fundamentals Summary
| DASPHARMA fundamental statistics | |
|---|---|
| Market cap | n/a |
| Earnings (TTM) | GH₵0 |
| Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs DASPHARMA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DASPHARMA income statement (TTM) | |
|---|---|
| Revenue | GH₵0 |
| Cost of Revenue | GH₵0 |
| Gross Profit | GH₵0 |
| Other Expenses | GH₵0 |
| Earnings | GH₵0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did DASPHARMA perform over the long term?
See historical performance and comparison